text
"['\n1. 요약재무정보\n하기 연결재무정보 및 재무정보는 한국채택국제회계기준에 따라 작성되었으며,제65기 연결재무정보 및 재무정보는 주주총회 승인 전 재무제표로 향후 정기주주총회에서 재무제표 승인 관련 안건이 부결되거나 수정이 발생한 경우 정정보고서를 통해 그 내용 및 사유를 반영할 예정입니다.\n요약연결재무정보\n국제약품(주) 및 종속기업 \xa0\xa0\n(단위 : 원)\n구 분\n제65기\n제64기\n제63기\n[유동자산]\n48,535,452,258\n48,197,308,387\n49,940,201,956\n-현금및현금성자산\n5,538,928,478\n7,866,062,183\n4,013,014,774\n-매출채권\n19,131,334,053\n20,652,657,728\n20,250,681,477\n-재고자산\n22,235,167,103\n16,540,406,112\n21,651,887,423\n-기타유동자산\n1,630,022,624\n3,138,182,364\n4,024,618,282\n[비유동자산]\n88,057,410,548\xa0\n91,585,738,297\n95,685,349,934\n-유형자산\n76,828,012,026\xa0\n80,044,733,529\n84,882,176,864\n-무형자산\n1,125,437,214\xa0\n1,333,272,730\n1,492,236,263\n-투자부동산\n3,444,971,576\xa0\n3,354,393,245\n3,488,952,649\n-기타비유동자산\n6,658,989,732\xa0\n6,853,338,793\n5,821,984,158\n자산총계\n136,592,862,806\xa0\n139,783,046,684\n145,625,551,890\n[유동부채]\n47,855,143,190\xa0\n54,516,684,923\n55,357,616,964\n[비유동부채]\n14,658,459,606\xa0\n16,678,553,018\n19,769,071,069\n부채총계\n62,513,602,796\xa0\n71,195,237,941\n75,126,688,033\n[자본금]\n20,195,149,000\xa0\n19,276,090,000\n18,400,520,000\n[주식발행초과금]\n2,076,939,192\xa0\n2,995,998,192\n3,871,568,192\n[기타포괄손익누계액]\n29,768,646,556\xa0\n29,430,639,780\n29,335,099,371\n[기타자본항목]\n15,706,379,971\xa0\n15,770,814,508\n15,816,353,383\n[이익잉여금]\n6,326,958,321\xa0\n1,094,519,493\n3,058,916,238\n지배기업소유주지분\n74,074,073,040\xa0\n68,568,061,973\n70,482,457,184\n비지배지분\n5,186,970\xa0\n19,746,770\n16,406,673\n자본총계\n74,079,260,010\xa0\n68,587,808,743\n70,498,863,857\n부채와자본총계\n136,592,862,806\xa0\n139,783,046,684\n145,625,551,890\n매출액\n126,583,402,933\xa0\n119,745,568,736\n130,394,720,787\n영업이익(손실)\n5,272,527,164\xa0\n(1,675,903,581)\n6,041,374,040\n당기순이익(손실)\n3,542,773,665\xa0\n(1,555,791,280)\n2,194,568,946\n\xa01.지배기업소유주지분\n3,557,333,465\xa0\n(1,559,131,377)\n2,203,001,015\n\xa02.비지배지분\n(14,559,800)\n3,340,097\n(8,432,069)\n기타포괄손익\n2,012,502,512\xa0\n(309,724,959)\n7,350,341,784\n당기총포괄이익(손실)\n5,555,276,177\xa0\n(1,865,516,239)\n9,544,910,730\n\xa01.지배기업소유주지분\n5,569,835,977\xa0\n(1,868,856,336)\n9,553,342,799\n\xa02.비지배지분\n(14,559,800)\n3,340,097\n(8,432,069)\n주당순이익(손실)\n184\xa0\n(81)\n120\n연결에 포함된 회사수\n1\xa0\n1\n1\n<종속기업 재무정보 요약>\n(2022년)\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,549,447\n97,256\n2,992,330\n(272,996)\n(2021년) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,661,479\n370,252\n4,018,304\n62,627\n(2020년) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,592,178\n307,625\n3,960,265\n(158,101)\n요약재무정보\n국제약품(주) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n(단위 : 원)\n구 분\n제65기\n제64기\n제63기\n[유동자산]\n47,872,340,430\xa0\n47,509,136,962\xa0\n49,174,515,891\xa0\n-현금및현금성자산\n5,309,615,691\xa0\n7,654,384,083\xa0\n3,658,329,420\xa0\n-매출채권\n18,850,395,307\xa0\n20,228,765,209\xa0\n19,929,859,420\xa0\n-재고자산\n22,078,821,355\xa0\n16,491,918,820\xa0\n21,569,134,807\xa0\n-기타유동자산\n1,633,508,077\xa0\n3,134,068,850\xa0\n4,017,192,244\xa0\n[비유동자산]\n87,116,481,391\xa0\n90,628,761,663\xa0\n94,837,294,329\xa0\n-유형자산\n76,668,342,346\xa0\n79,572,383,576\xa0\n84,465,524,125\xa0\n-무형자산\n1,077,738,761\xa0\n1,271,874,285\xa0\n1,489,062,824\xa0\n-투자부동산\n3,314,752,009\xa0\n3,453,461,341\xa0\n3,592,170,673\xa0\n-기타비유동자산\n6,055,648,275\xa0\n6,331,042,461\xa0\n5,290,536,707\xa0\n자산총계\n134,988,821,821\xa0\n138,137,898,625\xa0\n144,011,810,220\xa0\n[유동부채]\n47,637,353,361\xa0\n54,321,860,051\xa0\n55,168,831,048\xa0\n[비유동부채]\n14,539,844,444\xa0\n16,314,880,710\xa0\n19,415,080,745\xa0\n부채총계\n62,177,197,805\xa0\n70,636,740,761\xa0\n74,583,911,793\xa0\n[자본금]\n20,195,149,000\xa0\n19,276,090,000\xa0\n18,400,520,000\xa0\n[주식발행초과금]\n2,076,939,192\xa0\n2,995,998,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n29,668,637,929\xa0\n29,308,727,106\xa0\n29,236,392,939\xa0\n[기타자본항목]\n15,879,723,898\xa0\n15,944,158,435\xa0\n15,989,697,310\xa0\n[이익잉여금]\n4,991,173,997\xa0\n(23,815,869)\n1,929,719,986\xa0\n자본총계\n72,811,624,016\xa0\n67,501,157,864\xa0\n69,427,898,427\xa0\n자본과부채총계\n134,988,821,821\xa0\n138,137,898,625\xa0\n144,011,810,220\xa0\n종속·관계·공동기업\n투자주식의 평가방법\n원가법\n원가법\n원가법\n매출액\n123,598,850,791\xa0\n115,744,739,600\xa0\n126,514,615,485\xa0\n영업이익(손실)\n5,542,738,674\xa0\n(1,747,037,562)\n6,195,143,340\xa0\n당기순이익(손실)\n3,339,884,503\xa0\n(1,548,270,487)\n2,433,601,066\xa0\n기타포괄손익\n2,011,200,317\xa0\n(332,931,201)\n7,251,635,352\xa0\n당기총포괄손익\n5,351,084,820\xa0\n(1,881,201,688)\n9,685,236,418\xa0\n주당순이익(손실)\n173\xa0\n(80)\n132\n']"
